TKMR Stock Recent News Tekmira Pharmaceuticals Corp (TKMR) 13.84

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tekmira Pharmaceuticals Corp (TKMR) 13.84 $TKMR

Tekmira Pharma in Focus as the World Awaits Ebola Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 5:34PM CDT
Tekmira (TKMR) is in focus following Ebola outbreak.

Nasdaq stocks posting largest volume increases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Nasdaq stocks posting largest percentage decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Today's Dead Cat Bounce Stock Is Tekmira Pharmaceuticals (TKMR)
at The Street - Tue Aug 05, 9:01AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a "dead cat bounce" (down big yesterday but up big today) candidate

'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.

Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today
at The Street - Mon Aug 04, 9:24AM CDT
Tekmira Pharmaceuticals (TKMR) shares are gaining following reports that the FDA could reconsider its Ebola treatment as the outbreak of the disease worsens in Africa.

The Tekmira Ebola Trade May Already Be Over
at The Street - Mon Aug 04, 9:07AM CDT
CNN reports competing, secret Ebola therapy already saved lives of U.S. aid workers.

Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold
GlobeNewswire - Mon Jul 21, 11:19AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced an update on the TKM-Ebola Phase I clinical hold. The Company has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) and is preparing a Complete Response to the Agency. The Company anticipates this matter will be resolved by Q4, 2014.

Tekmira Receives $1.5 Million Milestone Payment
GlobeNewswire - Wed Jul 09, 6:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a $1.5 million milestone payment from Monsanto following completion of specified program developments. The development milestone is part of the research program under the Option Agreement Tekmira signed with the agriculture company, which we announced on January 13, 2014. The Option Agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones.

Why Tekmira Pharmaceuticals (TKMR) Stock Is Plunging Today
at The Street - Thu Jul 03, 10:59AM CDT
Tekmira Pharmaceuticals (TKMR) plunged Thursday after the company announced it had received verbal notice from the FDA of a clinical hold on the company's TKM-Ebola Phase I clinical trial.

Tekmira Receives Notice of Clinical Hold for TKM-Ebola Phase I Clinical Trial
GlobeNewswire - Thu Jul 03, 2:15AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has received verbal notice from the U. S. Food and Drug Administration (FDA) that the TKM-Ebola Phase I healthy volunteer clinical study has been placed on clinical hold. This notice applies only to this study.

Ebola Viral Infections - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nmqftt/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - Medicago Inc. - Zalicus Inc. - Summit Corporation plc - Vaxart, Inc. - Navigen Pharmaceuticals, Inc. - Humabs BioMed SA For more information visit http://www.researchandmarkets.com/research/nm...bola_viral
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 144

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 263

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 159

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 242

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 327

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

Franklin Universal Trust Distributions Explained: A Deep Dive

Updated Category News Views 225

Understanding Franklin Universal Trust's Distribution Sources In the investment landscape, knowing the sources of distributions can significantly inform investors about the health of their investments. Franklin Universal Trust (NYSE: FT) recently provided an update on its distribution sources, which is vital for shareholders seeking to gauge the Fund’s performance....

Continue Reading
Bitcoin Flat, Ethereum Up: Is This Your Accumulation Moment?

Updated Category News Views 149

Bitcoin's been stuck in neutral territory lately, trading flat as of Monday with a mild dip in volatility due to holiday-driven thin liquidity. It pushed up to $70,060 but faced serious resistance, retreating back into the $68,000 zone where it seems to be camping out. Volume? Yeah, that dropped a cool 17% from yesterday's action—so you know how traders get restless...

Continue Reading
Automotive Wiper Blade Market Set for Robust Expansion

Updated Category News Views 121

Anticipated Growth in the Automotive Wiper Blade Market The global automotive wiper blade market is poised for significant growth in the coming years. Projections estimate that the market value will climb to USD 11.5 billion by 2034, up from USD 6 billion in 2024. This increase signifies a compound annual growth rate (CAGR) of 6.8%. Key drivers of this growth include...

Continue Reading
Celebrated Financial Advisor Joins Ameriprise, Enhancing Services

Updated Category News Views 190

Gary Presslaff Joins Ameriprise Financial Team In a significant move for the financial services landscape, mentor Gary Presslaff has officially joined the ranks of Ameriprise Financial, Inc. (NYSE: AMP). With four decades of industry experience, Presslaff brings a wealth of knowledge and expertise, bolstering the team at Monumental Financial Planning located in Washington...

Continue Reading
Royal Mint Celebrates Iconic Metal Band with Special Coin

Updated Category News Views 237

Royal Mint Commemorative Coin for Iron Maiden's 50th Anniversary The Royal Mint has recently unveiled an impressive commemorative coin that celebrates the remarkable 50-year journey of the legendary heavy metal band, Iron Maiden. This special release is part of The Royal Mint's Music Legends series, which has previously honored iconic musicians such as Queen, Elton John,...

Continue Reading